Illustration by Fabio Buonocore
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 613, 626-628 (2023)
doi: https://doi.org/10.1038/d41586-023-00177-z
Updates & Corrections
-
Correction 27 January 2023: An earlier version of this feature incorrectly referred to GD2 as a protein.
References
Majzner, R. G. et al. Nature 603, 934–941 (2022).
Foy, S. P. et al. Nature https://doi.org/10.1038/s41586-022-05531-1 (2022).
Bai, Z. et al. Sci. Adv. 8, eabj2820 (2022).
Good, C. R. et al. Cell 184, 6081–6100 (2021).
Schmidt, R. et al. Science 375, eabj4008 (2022).
Carnevale, J. et al. Nature 609, 174–182 (2022).
Allen, G. M. et al. Science 378, eaba1624 (2022).
Li, H-S. et al. Science 378, 1227–1234 (2022).
Benjamin, R. et al. Lancet Haematol. 9, E833–E843 (2022).
Mackensen, A. et al. Nature Med. 28, 2124–2132 (2022).
Rurik, J. G. et al. Science 375, 91–96 (2022).
Svoboda, J. et al. Blood 140 (Suppl. 1), 4612–4614 (2022).
CRISPR cancer trial success paves the way for personalized treatments
Last-resort cancer therapy holds back disease for more than a decade
Cancer treatments boosted by immune-cell hacking
